Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

As the U.S. stock market reacts to tariff news and a wave of earnings reports, major indices like the S&P 500 and Nasdaq Composite are seeing upward movement. For investors considering smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area with potential value. These stocks can offer unique growth opportunities, especially when backed by strong financials, as we explore several promising candidates in this article.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8975	$6.46M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$121.65M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2651	$10.4M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.91	$89.18M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.45	$48.18M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.94	$52.92M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.24	$22.53M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9305	$85.11M	★★★★★☆
SideChannel (OTCPK:SDCH)	$0.04	$9.02M	★★★★★★

Click here to see the full list of 715 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Anebulo Pharmaceuticals (NasdaqCM:ANEB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for unintentional cannabis poisoning and related conditions in the United States, with a market cap of $39.83 million.

Operations: Anebulo Pharmaceuticals, Inc. currently does not have any reported revenue segments.

Market Cap: $39.83M

Anebulo Pharmaceuticals is a pre-revenue biotech firm with a market cap of US$39.83 million, focused on developing treatments for cannabis poisoning. The company recently raised nearly US$15 million through private placements, bolstering its cash runway beyond the previously forecasted two months. Despite its unprofitability and high share price volatility, Anebulo has reduced losses by 29.9% annually over the past five years and maintains no debt or long-term liabilities. Its management team and board of directors are considered experienced, which could support strategic decision-making as it progresses through clinical stages.

• Click to explore a detailed breakdown of our findings in Anebulo Pharmaceuticals' financial health report.
• Gain insights into Anebulo Pharmaceuticals' past trends and performance with our report on the company's historical track record.

CytoMed Therapeutics (NasdaqCM:GDTC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company developing novel cell-based immunotherapies for treating human cancers and degenerative diseases in Malaysia and Singapore, with a market cap of $30.47 million.

Operations: The company's revenue is solely derived from its Biotechnology (Startups) segment, totaling SGD 0.45 million.

Market Cap: $30.47M

CytoMed Therapeutics is a pre-revenue biopharmaceutical company with a market cap of US$30.47 million, focusing on innovative cell-based immunotherapies. Despite its unprofitability and high share price volatility, the company has not experienced significant shareholder dilution recently and maintains more cash than debt. CytoMed's management team is seasoned, although its board lacks experience. The company's strategic collaboration with SunAct Cancer Institute aims to advance clinical trials in cancer immunotherapy in India, potentially benefiting from local incentives to reduce research costs. Recent executive changes include the resignation of Co-CEO Dr Tan Wee Kiat for personal reasons.

• Get an in-depth perspective on CytoMed Therapeutics' performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into CytoMed Therapeutics' future.

Enzon Pharmaceuticals (OTCPK:ENZN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Enzon Pharmaceuticals, Inc., along with its subsidiaries, currently does not have significant operations and has a market cap of $11.10 million.

Operations: Currently, there are no reported revenue segments for Enzon Pharmaceuticals.

Market Cap: $11.1M

Enzon Pharmaceuticals, with a market cap of US$11.10 million, is pre-revenue and recently reported earnings of US$0.85 million for the first nine months of 2024. The company has no debt or long-term liabilities and maintains strong short-term asset coverage. Despite stable weekly volatility, its share price remains highly volatile over recent months. Enzon's board is seasoned with an average tenure of 3.6 years and recently expanded to include Stephen T. Wills as a director, who brings extensive financial expertise from his roles in other biopharmaceutical companies. A special committee was formed to explore strategic alternatives with Viskase Companies, Inc.

• Unlock comprehensive insights into our analysis of Enzon Pharmaceuticals stock in this financial health report.
• Explore historical data to track Enzon Pharmaceuticals' performance over time in our past results report.

Next Steps

• Jump into our full catalog of 715 US Penny Stocks here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com